Drug intelligence / Profile preview

ES-1901

Development stage: Preclinical
Lead developer: Eusol Biotech
Administration: Parenteral

Overview

ES-1901 is a preclinical-stage therapeutic candidate being developed by Eusol Biotech for the treatment of perioperative hyperglycemia. Perioperative hyperglycemia refers to elevated blood glucose levels during the surgical period, which can lead to increased risks of infection, delayed wound healing, and other post-operative complications. While specific details regarding its mechanism of action and molecular modality have not been publicly disclosed, the drug is part of Eusol Biotech's innovation pipeline aimed at improving surgical outcomes and metabolic management in clinical settings.

Targets

ESR1 (ERα)

Beyond the preview

Go deeper on ES-1901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ES-1901.

Explore the full profile